Progentec, an Oklahoma City-based leader in the development of nextgen diagnostics and digital therapeutics for the management of autoimmune diseases, completed a $5m Series A funding.
The round was led by Plains Venture Partners, the Oklahoma Seed Capital Fund and the Oklahoma Angel Capital Fund II, managed by i2E Management Company (Oklahoma City), with participation from NMC Health (Abu Dhabi), OCA Ventures (Chicago), Stanford University (Stanford), the Oklahoma Medical Research Foundation (Oklahoma City), Mayo Clinic, and Burns & Stowers Investments LLC (Norman, OK).
Led by CEO Mohan Purushothaman, Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically-validated diagnostic interventions with digital technologies.
The funding will provide go-to-market capital for the company’s CLIA laboratory and digital technologies for the management of lupus and will support new research into digital biomarkers and remote delivery of digital therapeutic programs.
FinSMEs
09/01/2020